181697-20-1

Basic information

• Product Name: 3',5'-DIFLUORO-2-PHENYLACETOPHENONE
• Synonyms: 3',5'-DIFLUORO-2-PHENYLACETOPHENONE
• CAS NO: 181697-20-1
• Molecular Formula: C₁₄H₁₀F₂O
• Molecular Weight: 232.23
• Mol File: 181697-20-1.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3',5'-DIFLUORO-2-PHENYLACETOPHENONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3',5'-DIFLUORO-2-PHENYLACETOPHENONE(181697-20-1)
• EPA Substance Registry System: 3',5'-DIFLUORO-2-PHENYLACETOPHENONE(181697-20-1)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 181697-20-1(Hazardous Substances Data)

Upstream product

• 103-82-2 phenylacetic acid 
• 216393-55-4 methyl 3,5-difluorobenzoate 
• 32085-88-4 3,5-difluorobenzaldehyde 
• 100-39-0 benzyl bromide 
• 7677-24-9 trimethylsilyl cyanide 

Downstream Products

• 181696-13-9 4-[3-(3,5-difluorophenyl)-5-methylisoxazol-4-yl]benzenesulfonamide 
• 181697-22-3 3-(3,5-difluorophenyl)-4-phenyl-5-methyl isoxazole 
• 1283117-55-4 6-(3,5-difluorophenyl)-4-(3-ethoxy-4-hydroxy-5-nitrophenyl)-5-phenyl-3,4-dihydropyrimidin-2(1H)-one 
• 181697-21-2 1-(3,5-difluorophenyl)-2-phenyl-ethan-1-one oxime 

Relevant articles and documents

Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics

The retinoid X receptors (RXR) are ligand-activated transcription factors involved in multiple regulatory networks as universal heterodimer partners for nuclear receptors. Despite their high therapeutic potential in many pathologies, targeting of RXR has only been exploited in cancer treatment as the currently available RXR agonists suffer from exceptional lipophilicity, poor pharmacokinetics (PK), and adverse effects. Aiming to overcome the limitations and to provide improved RXR ligands, we developed a new potent RXR ligand chemotype based on the nonsteroidal anti-inflammatory drug oxaprozin. Systematic structure-activity relationship analysis enabled structural optimization toward low nanomolar potency similar to the well-established rexinoids. Cocrystal structures of the most active derivatives demonstrated orthosteric binding, and in vivo profiling revealed superior PK properties compared to current RXR agonists. The optimized compounds were highly selective for RXR activation and induced RXR-regulated gene expression in native cellular and in vivo settings suggesting them as excellent chemical tools to further explore the therapeutic potential of RXR.

Substituted isoxazoles for the treatment of inflammation

A class of substituted isoxazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula (III) wherein R7 is selected from hydroxyl, lower alkyl, carboxyl, halo, lower carboxylalkyl, lower alkoxycarbonylalkyl, lower alkoxyalkyl, lower carboxyalkoxyalkyl, lower haloalkyl, lower haloalkylsulfonyloxy, lower hydroxyalkyl, lower aryl (hydroxylalkyl), lower carboxyaryloxyalkyl, lower alkoxycarbonylaryloxyalkyl, lower cycloalkyl, lower cycloalkylalkyl, and lower aralkyl; and wherein R8 is one or more radicals independently selected from hydrido, lower alkylsulfinyl, lower alkyl, cyano, carboxyl, lower alkoxycarbonyl, lower haloalkyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, lower arylamino, lower aminoalkyl, nitro, halo, lower alkoxy, aminosulfonyl, and lower alkylthio; or a pharmaceutically-acceptable salt thereof.